Comparison of inhibition of cutaneous histamine reaction of ebastine fast-dissolving tablet (20 mg) versus desloratadine capsule (5 mg): A randomized, double-blind, double-dummy, placebo-controlled, three-period crossover study in healthy, nonatopic adults

Clinical Therapeutics

Volumn 29, Issue 5, 2007, Pages 814-822

  Antonijoan, Rosa ^a   García Gea, Consuelo ^a   Puntes, Montserrat ^a   Pérez, Joselin ^a   Esbrí, Ramón ^b   Serra, Cristina ^b   Fortea, Josep ^b   Barbanoj, Manuel J ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b Almirall SA ^*  (Spain)

Author keywords

allergy; antihistamine; histamine challenge; lyophilizate; skin prick test

Indexed keywords

DESLORATADINE; EBASTINE; HISTAMINE; PLACEBO;

ADULT; ARTICLE; ASTHENIA; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INHIBITION; DRUG RESEARCH; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FEVER; HUMAN; HUMAN EXPERIMENT; MALE; MOUTH PAIN; NORMAL HUMAN; PHYSICAL EXAMINATION; PRICK TEST; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; SOMNOLENCE; SORE THROAT; SPAIN; URTICARIA; VISUAL ANALOG SCALE; XEROSTOMIA;

ADOLESCENT; ADULT; BUTYROPHENONES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HISTAMINE; HISTAMINE H1 ANTAGONISTS; HUMANS; LORATADINE; MALE; PAIN MEASUREMENT; PIPERIDINES; PRURITUS; SKIN; SKIN TESTS;

EID: 34547679956     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.05.001     Document Type: Article

References (34)

1. Van Cauwenberge P., De Belder T., and Sys L. A review of the second-generation antihistamine ebastine for the treat ment of allergic disorders. Expert Opin Pharmacother 5 (2004) 1807-1813
2. Storms W.W. Clinical studies of the efficacy and tolerability of ebastine 10 or 20 mg once daily in the treatment of seasonal allergic rhinitis in the US. Drugs 52 Suppl 1 (1996) 20-25
3. Frank Jr. H., Gillen M., Rohatagi S.S., et al., Ebastine Study Group. A double-blind, placebo-controlled study of the efficacy and safety of ebastine 20 mg once daily given with and without food in the treatment of seasonal allergic rhinitis. J Clin Pharmacol 42 (2002) 1097-1104
4. Ratner P., Hampel Jr. F., and Gispert J. Efficacy of ebastine in the control of nasal congestion associated with allergic rhinitis. Methods Find Exp Clin Pharmacol 25 (2003) 111-115
5. Ratner P., Hampel Jr. F., Van Bavel J., and Howland III W. Efficacy and safety of ebastine 20 mg compared to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled study. Int Arch Allergy Immunol 133 (2004) 371-379
6. Picado Valles C., Cadahia Garcia A., Cistero Bahima A., et al. Ebastine in perennial allergic rhinitis. Ann Allergy 67 (1991) 615-618
7. Bousquet J., Gaudano E.M., Palma Carlos A.G., Staudinger H., and Multicentre Study Group. A 12-week, placebocontrolled study of the efficacy and safety of ebastine, 10 and 20 mg once daily, in the treatment of perennial allergic rhinitis. Allergy 54 (1999) 562-568
8. Peyrí J., Vidal J., Marrón J., et al. Ebastine in chronic urticaria: A double-blind placebo controlled study. J Dermatol Treat 2 (1991) 51-53
9. Kalis B. Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria in adults. Drugs 52 Suppl 1 (1996) 30-34
10. Gehanno P., Bremard-Oury C., and Zeisser P. Comparison of ebastine to cetirizine in seasonal allergic rhinitis in adults. Ann Allergy Asthma Immunol 76 (1996) 507-512
11. Hampel Jr. F., Howland III W., Van Bavel J., and Ratner P. A randomized, double-blind, placebo-controlled study comparing the efficacy and safety of ebastine (20 mg and 10 mg) to loratadine 10 mg once daily in the treatment of seasonal allergic rhinitis. J Investig Allergol Clin Immunol 14 (2004) 56-63
12. Ratner P.H., Lim J.C., Georges G.C., and Ebastine Study Group. Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treat ment of seasonal allergic rhinitis. J Allergy Clin Immunol 105 (2000) 1101-1107
13. Ratner P., Falques M., Chuecos F., et al. Meta-analysis of the efficacy of ebastine 20 mg compared to loratadine 10 mg and placebo in the symptomatic treatment of seasonal allergic rhinitis. Int Arch Allergy Immunol 138 (2005) 312-318
14. Vincent J., Limiñana R., Meredith P.A., and Reid J.L. The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects. Br J Clin Pharmacol 26 (1988) 497-502
15. Hurst M., and Spencer C.M. Ebastine: An update of its use in allergic disorders. Drugs 59 (2000) 981-1006
16. Lasseter K.C., Dilzer S.C., Vargas R., et al. Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: A phase I openlabel study. Clin Pharmacokinet 43 (2004) 121-129
17. Gillen M.S., Miller B., Chaikin P., and Morganroth J. Effects of supratherapeutic doses of ebastine and terfena dine on the QT interval [published correction appears in Br J Clin Pharmacol. 2001;52:343]. Br J Clin Pharmacol 52 (2001) 201-204
18. Malik M. Effects of supratherapeutic doses of ebastine and terfenadine on the QT interval. Br J Clin Pharmacol 54 (2002) 682-683
19. Bilbao, Spain. Poster OC9. Salva M., Carreno B., Pintos M., et al. Phase I, single dose, open-label, randomized, crossover bioequivalence studies of ebastine 10 and 20 mg fast-dissolving tablets in healthy male volunteers. Presented at: InterasmaEAACI Joint Meeting (November 28, 2004)
20. 1-receptor antagonist, in patients with seasonal allergic rhinitis: Assessment during the spring and fall allergy seasons. Clin Drug Invest 21 (2001) 25-32
21. Desager J.P., and Horsmans Y. Pharmacokinetic-pharmacodynamic relationships of H1-antihistamines. Clin Pharmacokinet 28 (1995) 419-432
22. (Suppl). Herron J.M., Padhi D., Affrime M.B., et al. Dose-proportionality, linearity, and pharmacokinetics of deslorata dine in healthy adults. Abstract 1126. J Allergy Clin Immunol 105 (2000) S385
23. Demoly P., Michael F.B., and Bousquet J. In-vivo methods for study of allergy, skin tests: Techniques and interpreta tion. In: Middleton Jr. E., Reed C., Ellis E.F., and Yunginger J.W. (Eds). Allergy: Principles and Practice. 5th ed (1998), Mosby, London, England 430-439
24. Barbanoj M.J., Antonijoan R.M., Garcia-Gea C., et al. A study comparing the inhibitory effects of single and repeated oral doses of ebastine and fexofenadine against histamine-induced skin reactivity. Int Arch Allergy Immunol 132 (2003) 263-267
25. In: Van Riezel H., and Segal M. (Eds). Description of Patient-Rated General Symptom Scales. Comparative Evaluation of Rating Scales for Clinical Pharmacology (1988), Elsevier-Science Publishers BV, Amsterdam, The Netherlands 59-62
26. Skassa-Brociek W., Manderscheid J.C., Michel F.B., and Bousquet J. Skin test reactivity to histamine from infancy to old age. J Allergy Clin Immunol 80 (1987) 711-716
27. Van Niekerk C.H., and Prinsloo A.E. Effect of skin pigmentation on the response to intradermal histamine. Int Arch Allergy Appl Immunol 76 (1985) 73-75
28. Frossard N., Benabdesselam O., Purohit A., et al. Activity of ebastine (10 and 20 mg) and cetirizine at 24 hours of a steady treatment in the skin of healthy volunteers. Fundam Clin Pharmacol 14 (2000) 409-413
29. Grant J.A., Danielson L., Rihoux J.P., and DeVos C. A double-blind, single-dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: Suppression of histamineinduced wheal and flare response for 24 h in healthy male subjects. Allergy 54 (1999) 700-707
30. Barbanoj M.J., Garcia-Gea C., Morte A., et al. Central and peripheral evaluation of rupatadine, a new antihistamine/platelet-activating factor antagonist, at different doses in healthy volunteers. Neuropsychobiology 50 (2004) 311-321
31. Gispert J., Antonijoan R., Barbanoj M., et al. Efficacy of ebastine, cetirizine, and loratadine in histamine cutane ous challenges. Ann Allergy Asthma Immunol 89 (2002) 259-264
32. Fu Y., Yang S., Jeong S.H., et al. Orally fast disintegrating tablets: Developments, technologies, taste-masking and clinical studies. Crit Rev Ther Drug Carrier Syst 21 (2004) 433-476
33. Barbanoj M.J., Garcia-Gea C., Antonijoan R., et al. Evaluation of the cognitive, psychomotor and pharma cokinetic profiles of rupatadine, hydroxyzine and cetirizine, in combination with alcohol, in healthy volunteers. Hum Psychopharmacol 21 (2006) 13-26
34. Monroe E.W., Daly A.F., and Shalhoub R.F. Appraisal of the validity of histamine-induced wheal and flare to predict the clinical efficacy of antihistamines. J Allergy Clin Immunol 99 (1997) 5798-5806